Erin S LeBlanc1, Manisha Desai, Nancy Perrin, Jean Wactawski-Wende, JoAnn E Manson, Jane A Cauley, Yvonne L Michael, Jean Tang, Catherine Womack, Yiqing Song, Karen C Johnson, Mary J O'Sullivan, Nancy Woods, Marcia L Stefanick. 1. From the 1Center for Health Research, Kaiser Permanente Northwest, Portland, OR; 2Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA; 3University of Buffalo, Buffalo, NY; 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 5Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; 6Department of Epidemiology and Biostatistics, Drexel University School of Public Health, Philadelphia, PA; 7Department of Medicine, Stanford University School of Medicine, Stanford, CA; 8University of Tennessee Health Science Center, Memphis, TN; 9Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA; 10Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN; 11University of Miami, Miami, FL; 12Biobehavioral Nursing, University of Washington, Seattle, WA; and 13Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Abstract
OBJECTIVE: This study aims to determine whether vitamin D levels are associated with menopause-related symptoms in older women. METHODS: A randomly selected subset of 1,407 women, among 26,104 potentially eligible participants of the Women's Health Initiative Calcium and Vitamin D trial of postmenopausal women aged 51 to 80 years, had 25-hydroxyvitamin D [25(OH)D] levels measured at the Women's Health Initiative Calcium and Vitamin D trial baseline visit. Information about menopause-related symptoms at baseline was obtained by questionnaire and included overall number of symptoms and composite measures of sleep disturbance, emotional well-being, and energy/fatigue, as well as individual symptoms. After exclusions for missing data, 530 women (mean [SD] age, 66.2 [6.8] y) were included in these analyses. RESULTS: Borderline significant associations between 25(OH)D levels and total number of menopausal symptoms were observed (with P values ranging from 0.05 to 0.06 for fully adjusted models); however, the effect was clinically insignificant and disappeared with correction for multiple testing. No associations between 25(OH)D levels and composite measures of sleep disturbance, emotional well-being, or energy/fatigue were observed (P's > 0.10 for fully adjusted models). CONCLUSIONS: There is no evidence for a clinically important association between serum 25(OH)D levels and menopause-related symptoms in postmenopausal women.
RCT Entities:
OBJECTIVE: This study aims to determine whether vitamin D levels are associated with menopause-related symptoms in older women. METHODS: A randomly selected subset of 1,407 women, among 26,104 potentially eligible participants of the Women's Health Initiative Calcium and Vitamin D trial of postmenopausal women aged 51 to 80 years, had 25-hydroxyvitamin D [25(OH)D] levels measured at the Women's Health Initiative Calcium and Vitamin D trial baseline visit. Information about menopause-related symptoms at baseline was obtained by questionnaire and included overall number of symptoms and composite measures of sleep disturbance, emotional well-being, and energy/fatigue, as well as individual symptoms. After exclusions for missing data, 530 women (mean [SD] age, 66.2 [6.8] y) were included in these analyses. RESULTS: Borderline significant associations between 25(OH)D levels and total number of menopausal symptoms were observed (with P values ranging from 0.05 to 0.06 for fully adjusted models); however, the effect was clinically insignificant and disappeared with correction for multiple testing. No associations between 25(OH)D levels and composite measures of sleep disturbance, emotional well-being, or energy/fatigue were observed (P's > 0.10 for fully adjusted models). CONCLUSIONS: There is no evidence for a clinically important association between serum 25(OH)D levels and menopause-related symptoms in postmenopausal women.
Authors: Judith K Ockene; David H Barad; Barbara B Cochrane; Joseph C Larson; Margery Gass; Sylvia Wassertheil-Smoller; JoAnn E Manson; Vanessa M Barnabei; Dorothy S Lane; Robert G Brzyski; Milagros C Rosal; Judy Wylie-Rosett; Jennifer Hays Journal: JAMA Date: 2005-07-13 Impact factor: 56.272
Authors: Amy E Millen; Jean Wactawski-Wende; Mary Pettinger; Michal L Melamed; Frances A Tylavsky; Simin Liu; John Robbins; Andrea Z LaCroix; Meryl S LeBoff; Rebecca D Jackson Journal: Am J Clin Nutr Date: 2010-03-10 Impact factor: 7.045
Authors: Vanessa M Barnabei; Barbara B Cochrane; Aaron K Aragaki; Ingrid Nygaard; R Stan Williams; Peter G McGovern; Ronald L Young; Ellen C Wells; Mary Jo O'Sullivan; Bertha Chen; Robert Schenken; Susan R Johnson Journal: Obstet Gynecol Date: 2005-05 Impact factor: 7.661
Authors: Douglas W Levine; Daniel F Kripke; Robert M Kaplan; Megan A Lewis; Michelle J Naughton; Deborah J Bowen; Sally A Shumaker Journal: Psychol Assess Date: 2003-06
Authors: Marcia L Stefanick; Barbara B Cochrane; Judith Hsia; David H Barad; James H Liu; Susan R Johnson Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Rowan T Chlebowski; Karen C Johnson; Charles Kooperberg; Mary Pettinger; Jean Wactawski-Wende; Tom Rohan; Jacques Rossouw; Dorothy Lane; Mary Jo O'Sullivan; Shagufta Yasmeen; Robert A Hiatt; James M Shikany; Mara Vitolins; Janu Khandekar; F Allan Hubbell Journal: J Natl Cancer Inst Date: 2008-11-11 Impact factor: 13.506
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335